Compare CHCT & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | ETON |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.7M | 683.7M |
| IPO Year | 2015 | 2018 |
| Metric | CHCT | ETON |
|---|---|---|
| Price | $17.55 | $24.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $18.00 | ★ $39.33 |
| AVG Volume (30 Days) | 144.6K | ★ 471.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.98% | N/A |
| EPS Growth | ★ 134.78 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $121,195,000.00 | $79,950,000.00 |
| Revenue This Year | $9.06 | $40.90 |
| Revenue Next Year | $8.61 | $47.23 |
| P/E Ratio | $217.38 | ★ N/A |
| Revenue Growth | 4.67 | ★ 104.94 |
| 52 Week Low | $13.23 | $13.09 |
| 52 Week High | $18.22 | $27.29 |
| Indicator | CHCT | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 68.15 | 54.47 |
| Support Level | $16.03 | $16.38 |
| Resistance Level | $18.22 | N/A |
| Average True Range (ATR) | 0.32 | 1.23 |
| MACD | 0.20 | -0.15 |
| Stochastic Oscillator | 98.57 | 40.16 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.